Elevation Oncology, Inc. (ELEV)
NASDAQ: ELEV · Real-Time Price · USD
0.607
-0.042 (-6.53%)
At close: Feb 21, 2025, 4:00 PM
0.610
+0.003 (0.43%)
After-hours: Feb 21, 2025, 7:06 PM EST
Elevation Oncology Stock Forecast
ELEV's stock price has decreased by -78.31% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Elevation Oncology stock have an average target of 7.20, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 1,085.38% from the current stock price of 0.61.
Analyst Consensus: Buy
* Price targets were last updated on Jan 14, 2025.
Analyst Ratings
The average analyst rating for Elevation Oncology stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +887.82% | Jan 14, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 3, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $7 | Buy | Reiterates | $7 | +1,052.45% | Dec 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +887.82% | Dec 13, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $5 | Buy | Reiterates | $5 | +723.18% | Dec 6, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.87
from -1.34
EPS Next Year
-0.93
from -0.87
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | n/a | |||
| Avg | n/a | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.85 | -0.86 | -0.61 | |||
| Avg | -0.87 | -0.93 | -0.99 | |||
| Low | -0.92 | -0.96 | -1.33 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.